CB 1954: From the walker tumor to NQ02 and VDEPT

Current Pharmaceutical Design

Volumn 9, Issue 26, 2003, Pages 2091-2104

  Knox, Richard J ^a   Burke, Philip J ^c   Chen, Shiuan ^a   Kerr, David J ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b RADCLIFFE INFIRMARY   (United Kingdom)

^c Enact Pharma PLC   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 CARBAMOYLMETHYL 3 CARBAMOYL 1,4 DIHYDROPYRIDINE; 1,4 DIHYDROPYRIDINE DERIVATIVE; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ADENOVIRUS VECTOR; ALLOPURINOL; AMIDE; CHLORAMBUCIL; CISPLATIN; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; DIHYDROLIPOAMIDE DEHYDROGENASE; DNA; EP 0152 R; MELATONIN; MELPHALAN; MISONIDAZOLE; NICOTINAMIDE RIBOSIDE; NITROREDUCTASE; OXIDOREDUCTASE; PRODRUG; PYRIDINIUM DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM CANCER; DNA CROSS LINKING; DRUG ACTIVATION; DRUG METABOLISM; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ESCHERICHIA COLI; GENE THERAPY; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; STRUCTURE ANALYSIS; URINARY TRACT DISEASE; VIRAL GENE DELIVERY SYSTEM; WALKER CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; CARCINOMA 256, WALKER; CELL SURVIVAL; ESCHERICHIA COLI; GENE THERAPY; HUMANS; NITROREDUCTASES; PRODRUGS; QUINONE REDUCTASES; RATS; TUMOR CELLS, CULTURED;

EID: 0141426663     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033454108     Document Type: Review

References (98)

1. Cobb LM, Connors TA, Elson LA, Khan AH, Mitchley BC, Ross WC, et al. Biochem Pharmacol 1969; 18: 1519-27.
2. Connors TA, Melzack DH. Int J Cancer 1971; 7: 86-91
3. Workman P, Morgan JE, Talbot K, Wright KA, Donaldson J, Twentyman PR. Cancer Chemother Pharmacol 1986; 16: 9-14.
4. Ross WCJ, Mitchley BCV. Ann Rep Br Empire Cancer Campn 1950; 42: 70.
5. Khan AH, Ross WCJ. Chem Biol Interact 1969; 1: 27-47.
6. Khan AH, Ross WCJ. Chem Biol Interact 1971; 4: 11-22.
7. Sheard CE, Double JA, Berenbaum MC. Br J Cancer, 1971; 25: 838-844.
8. Phillips BJ, Ambrose EJ. Nature 1971; 231: 146-147.
9. Kavi BR, Bhisey AN, Bapat CV. Ind J Cancer 1975; 295-301.
10. Bhat AV, Kesava Rao KV, Bapat CV. Ind J Cancer 1977; 14: 132-135.
11. Double JA, Bibby MC. Br J Cancer 1983; 48: 739-42.
12. Cobb LM. Toxicol Appl Pharmacol 1970; 17: 231-238.
13. Venitt S. Chem Biol Interact 1971; 3: 177-91.
14. Mandel HG, Connors TA, Melzack DH, Merai K. Cancer Res 1974; 34: 275-280.
15. Connors TA. In Cancer Chemotherapy HM. Pinedo ed; Excerpta Medica: Amsterdam 1981; 3: pp. 32-74.
16. Connors TA, Mandel HG, Melzack DH. Int J Cancer 1972; 9: 126-132.
17. Hickman JA, Melzack DH. Biochem Pharmacol 1975; 24: 1947-1952.
18. Hickman JA, Melzack DH. Biochem Pharmacol 1976; 25: 2489-2491.
19. Connors TA, Mandel HG, Melzack DH. Int J Cancer 1972; 9: 126-32.
20. Tisdale MJ, Habberfield AD. Biochem Pharmacol 1980; 29: 2845-2853.
21. Tisdale MJ, Phillips BJ. Biochem Pharmacol 1975; 24: 211-217.
22. Tisdale MJ, Phillips BJ. Biochem Pharmacol 1975; 24: 1271-1276.
23. Tisdale MJ, Phillips B.I. Biochem Pharmacol 1976; 25: 2365-2370.
24. Tisdale MJ, Phillips B.I. Biochem Pharmacol 1976; 25: 1831-1836.
25. Tisdale MJ, Phillips B.I. Biochem Pharmacol 1978; 27: 947-52.
26. Walling JM, Stratford IJ, Stevens MA. Int J Radiat Oncol Biol Phys 1984; 10: 1661-1664.
27. Jarman M, Melzack DH, Ross WC. J. Biochem Pharmacol 1976; 25: 2475-2478.
28. Workman P, White RAS, Talbot K. Cancer Chemother Pharmacol 1986; 16: 1-8.
29. Melzack DH. University of London 1972.
30. Stratford IJ, Williamson C, Hoe S, Adams GE. Radiat Res 1981; 88: 502-509.
31. Walling JM, Stratford IJ, Adams GE. Int J Radiat Biol 1987; 52: 31-41.
32. Kandaiya S. Int J Radiat Biol Relat Stud Phys Chem Med 1985; 48: 441-6.
33. Chapman JD, Raleigh JAPJE, Ngan J, Shum FY, Meeker BE, Urtasun RC. Proc 6th Int Cong Radiation Res 1979; 885-892.
34. Tisdale MJ. Chem Biol Interact 1971; 3: 95-107.
35. Roberts JJ, Friedlos F, Knox RJ. Biochem Biophys Res Commun 1986; 140: 1073-8.
36. Knox RJ, Friedios F, Jarman M, Roberts JJ. Biochem Pharmacol 1988; 37: 4661-9.
37. Boland MP, Knox RJ, Roberts JJ. Biochem Pharmacol 1991; 41: 867-75.
38. Knox RJ, Friedlos F, Marchbank T, Roberts JJ. Biochem Pharmacol 1991; 42: 1691-7.
39. Knox RJ, Friedlos F, Biggs PJ, Flitter WD, Gaskell M, Goddard P, et al. Biochem Pharmacol 1993; 46: 797-803.
40. Knox RJ, Lydall DA, Friedlos F, Basham C, Rawlings CJ, Roberts JJ. Mutat Res 1991; 255: 227-40.
41. Knox RJ, Lydall DA, Friedlos F, Basham C, Roberts JJ. Biochim Biophys Acta 1987; 908: 214-23.
42. Friedlos F, Quinn J, Knox RJ, Roberts JJ. Biochem Pharmacol 1992; 43: 1249-54.
43. Knox RJ, Friedlos F, Lydall DA, Roberts JJ. Cancer Res 1986; 46: 1972-9.
44. Knox RJ, Friedlos F, Boland MP. Cancer Metastasis Rev 1993; 12: 195-212.
45. Knox RJ, Boland MP, Friedlos F, Coles B, Southan C, Roberts JJ. Biochem Pharmacol 1988; 37, 4671-7.
46. Riley RJ, Workman P. Biochem Pharmacol 1992; 43: 1657-69.
47. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. Chem Biol Interact 2000; 129: 77-97.
48. Friedlos F, Jarman M, Davies LC, Boland MP, Knox RJ. Biochem Pharmacol 1992; 44: 25-31.
49. Roberts JJ, Marchbank T, Kotsaki-Kovatsi VP, Boland MP, Friedlos F, Knox RJ. Biochem Pharmacol 1989; 38: 4137-43.
50. Talalay P, Fahey JW, Holtzclaw WD, Prestera T, Zhang Y. Toxicol Lett 1995; 82-83: 173-9.
51. Zhang Y, Talalay P, Cho CG, Posner GH. Proc Natl Acad Sci USA 1992; 89: 2399-403.
52. Schlager JJ, Powis G. Int J Cancer 1990; 45: 403-9.
53. Belinsky M, Jaiswal AK. Cancer Metastasis Rev 1993; 12: 103-17.
54. Beall HD, Murphy AM, Siegel D, Hargreaves RH, Butler J, Ross D. Mol Pharmacol 1995; 48, 499-504.
55. Berger MS, Talcott RE, Rosenblum ML, Silva M, Ali-Osman F, Smith MT. J Toxicol Environ Health 1985; 16: 713-719.
56. Okamura T, Kurisu K, Yamamoto W, Takano H, Nishiyama M. Int J Oncol 2000; 16: 295-303
57. Phillips RM, de la Cruz A, Traver RD, Gibson NW. Cancer Res 1994; 54: 3766-71.
58. Pan SS, Forrest GL, Akman SA, Hu LT. Cancer Res 1995; 55: 330-5.
59. Jaiswal AK. Free Radic Biol Med 2000; 29: 254-62.
60. Cresteil T, Jaiswal AK. Biochem Pharmacol 1991; 42: 1021-7.
61. Joseph P, Xie T, Xu Y, Jaiswal AK. Oncol Res 1994; 6: 525-32.
62. Schor NA, Cornelisse CJ. Cancer Res 1983; 43: 4850-4855.
63. Siegel D, Ross D. Free Radic Biol Med 2000; 29: 246-53.
64. Friedlos F, Biggs PJ, Abrahamson JA, Knox RJ. Biochem Pharmacol 1992; 44: 1739-43.
65. Siegel D, Ryder J, Ross D. Toxicol Lett 2001; 125: 93-8.
66. Chen S, Knox R, Lewis AD, Friedlos F, Workman P, Deng PS, et al. Mol Pharmacol 1995; 47: 934-9.
67. Chen S, Knox R, Wu K, Deng PSK, Zhou D, Bianchet MA, Amzel LM. J Biol Chem 1997; 272: 1437-9.
68. Wu K, Eng E, Knox R, Chen S. Arch Biochem Biophys 2001; 385: 203-8.
69. Mehta LK, Hobbs S, Chen S, Knox RJ, Parrick J. Anticancer Drugs 1999; 10: 777-83.
70. Melton RG, Knox RJ. eds. Enzyme-prodrug strategies for cancer therapy, Kluwer Academic/Plenum: New York 1999.
71. Anlezark GM, Melton RG, Sherwood RF, Coles B, Friedlos F, Knox RJ. Biochem Pharmacol 1992; 44: 2289-95.
72. Knox RJ, Friedlos F, Sherwood RF, Melton RG, Anlezark GM. Biochem Pharmacol 1992; 44: 2297-301.
73. Friedlos F, Knox RJ. Biochem Pharmacol 1992; 44: 631-5.
74. Knox RJ, Friedlos F, Jarman M, Davies LC, Goddard P, Anlezark GM, et al. Biochem Pharmacol 1995; 49: 1641-1647.
75. Knox RJ. In Enzyme Prodrug Strategies for Cancer Therapy RG. Melton, RJ. Knox, eds, Kluwer Academic/Plenum Press: New York, 1999; pp. 97-131.
76. Knox RJ. In Enzyme Prodrug Strategies for Cancer Therapy RG. Melton, RJ. Knox, eds, Kluwer Academic/Plenum Press: New York, 1999; pp. 209-243.
77. Connors TA. Gene Therapy 1995; 2: 1-9.
78. Bridgewater JA, Springer CJ, Knox RJ, Minton NP, Michael NP, Collins MK. Eur J Cancer 1995; 31a: 2362-70.
79. Bailey SM, Knox RJ, Hobbs SM, Jenkins TC, Mauger AB, Melton RG, et al. Gene Ther 1996; 3: 1143-50.
80. Bridgewater JA, Knox RJ, Pitts JD, Collins MK, Springer CJ. Hum Gene Ther 1997; 8: 709-717.
81. Green NK, Youngs DJ, Neoptolemos JP, Friedlos F, Knox RJ, Springer CJ, et al. Cancer Gene Ther 1997; 4: 229-238.
82. McNeish IA, Green NK, Gilligan MG, Ford MJ, Mautner V, Young LS, et al. Gene Ther 1998; 5: 1061-1069.
83. Weedon SJ, Green NK, McNeish IA, Gilligan MG, Mautner V, Wrighton CJ, et al. Int J Cancer 2000; 86: 848-54.
84. Chung-Faye G, Palmer D, Anderson D, Clark J, Downes M, Baddeley J, et al. Clin Cancer Res 2001; 7: 2662-8.
85. Wu K, Knox R, Sun XZ, Joseph P, Jaiswal AK, Zhang D, et al. Arch Biochem Biophys 1997; 347: 221-8.
86. Jaiswal AK, Burnett P Adesnik M, Wesley MO. Biochemistry 1990; 29: 1899-1906.
87. Jaiswal AK. J Biol Chem 1994; 269: 14502-8.
88. Knox RJ, Jenkins TC, Hobbs SM, Chen S, Melton RG, Burke PJ. Cancer Res 2000; 60: 4179-86.
89. Liao S, Dulaney JT, Willianis-Ashman HG. J Biol Chem 1962; 237: 2981-2987.
90. Liao S, Williams-Ashman HG. Biochem Biophys Res Comm 1961; 4: 208-213.
91. Zhao Q, Yang XL, Holtzclaw WD, Talalay P. Proc Natl Acad Sci USA 1997; 94: 1669-74.
92. Kodama T, Wakui H, Komatsuda A, Imai H, Miura AB, Tashima Y. Nephrol Dial Transplant, 1997; 12: 1453-60.
93. Nosjean O, Ferro M, Coge F, Beauverger P, Henlin JM, Lefoulon F, et al. Biol Chem 2000; 275; 31311-7.
94. Nosjean O, Nicolas JP, Klupsch F, Delagrange P, Canet E, Boutin JA. Biochem Pharmacol 2001; 61: 1369-79.
95. Knox RJ, Melton RG, Sharma SK, Burke PJ. Br J Cancer 2000; 83(Suppl. 1): 70.
96. Chen L, Waxman DJ. Cytochrome P450 gene-directcd enzyme prodrug therapy (GDEPT) for cancer. Curr Pharm Des 2002; 8(15): 1405-16.
97. Denny WA. Nitroreductase-based GDEPT. Curr Pharm Des 2002; 8(15): 1349-61.
98. McNally VA, Patterson AV, Williams KJ, Cowen RL, Stratford IJ, Jaffar M. Antiangiogenic bioreductive and gene therapy approaches to the treatment of hypoxic tumours. Curr Pharm Des 2002; 8(15): 1319-33.